Sugi Predict

Sugi Predict / Compounds / SCHEMBL2214853

SCHEMBL2214853

SCHEMBL2214853

Cc1ccc2[nH]c(C(=O)O)nc2c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIN1 Q13526 3/20 0.76
▸ MEN1 O00255 5/20 0.47
▸ KMT2A Q03164 5/20 0.47
▸ MAPT P10636 4/20 0.47
▸ CYP1A2 P05177 2/20 0.47
▸ CYP2C9 P11712 2/20 0.47
▸ CYP2C19 P33261 2/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ HRH4 Q9H3N8 1/20 0.46
▸ RECQL P46063 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ HSD17B10 Q99714 3/20 0.43
▸ TP53 P04637 1/20 0.43
▸ RHEB Q15382 1/20 0.42
▸ TDP1 Q9NUW8 2/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ HPGD P15428 2/20 0.42
▸ HTT P42858 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28379872 0.88 PIN1 (0.58) PIN1MEN1KMT2AMAPTCYP1A2
SCHEMBL5509574 0.86 PIN1 (1.00) PIN1KMT2ACYP1A2ALDH1A1HRH4
SCHEMBL26241758 0.86 PIN1 (0.57) PIN1MEN1KMT2AMAPTCYP1A2
SCHEMBL30707844 0.85 PIN1 (0.55) PIN1MEN1KMT2AMAPTCYP1A2
SCHEMBL21119736 0.83 PIN1 (0.54) PIN1MEN1KMT2AMAPTCYP1A2
SCHEMBL7705454 0.82 PIN1 (0.53) PIN1MEN1KMT2AMAPTCYP1A2
SCHEMBL30642943 0.82 PIN1 (0.53) PIN1MEN1KMT2AMAPTCYP1A2
SCHEMBL4811045 0.81 PIN1 (0.54) PIN1MAPTALDH1A1RHEBKDM4E
SCHEMBL29086759 0.79 TP53 (0.60) PIN1MEN1KMT2AMAPTCYP1A2
SCHEMBL30912931 0.79 TP53 (0.60) PIN1MEN1KMT2AMAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014130759-A1 METHODS OF USING HISTAMINE RECEPTOR AGONISTS AND ANTAGONISTS UNIVERSITY OF ROCHESTER (US) 2014-08-28 — — WO claimed
WO-2012175823-A1 NOVEL HYBRID ORGANIC/INORGANIC IM-22 SOLID, AND USE THEREOF IN THE SEPARATION OF MULTI-BRANCHED PARAFFINS FROM LINEAR AND SINGLE-BRANCHED PARAFFINS IFP Energies Nouvelles (FR) 2012-12-27 — — WO claimed
EP-1545532-A2 HETEROCYCLIC COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2005-06-29 — — EP claimed
US-20040058934-A1 Heterocyclic compounds JANSSEN PHARMACEUTIC, N.V. (BE) 2004-03-25 — — US claimed
WO-2004022060-A2 (1H-BENZOIMIDAZOL-2-YL)-(PIPERAZINYL)-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS JANSSEN PHARMACEUTICA, N.V. (BE) 2004-03-18 — — WO claimed
US-4662905-A REACTION PRODUCT OF COPPER SALT AND AN IMIDAZOLE, PYRAZOLE, TRIAZOLE, OR TETRAZOLE Itaru Todoriki, Director of Agency of Industrial Science and Technology (JP) 1987-05-05 — — US claimed
EP-0000574-B1 BENZIMIDAZOLE-2 DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR THE PREPARATION OF MEDICAMENTS CIBA-GEIGY AG (CH) 1982-08-04 — — EP claimed
EP-0000574-A1 Benzimidazole-2 derivatives, their preparation and their use for the preparation of medicaments CIBA-GEIGY AG (CH) 1979-02-07 — — EP claimed
EP-4634156-A1 SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd (KY) 2025-10-22 — — EP disclosed
US-12234398-B2 Metal organic framework (MOF) glass composite comprising metal halide perovskite THE UNIVERSITY OF QUEENSLAND (AU) 2025-02-25 — — US disclosed
US-20240376377-A1 A METAL ORGANIC FRAMEWORK (MOF) GLASS COMPOSITE COMPRISING METAL HALIDE PEROVSKITE THE UNIVERSITY OF QUEENSLAND (AU) 2024-11-14 — — US disclosed
WO-2024204299-A1 CARBON MATERIAL, MATERIAL COMPOSITION AND METHOD FOR PRODUCING CARBON MATERIAL 積水化学工業株式会社 2024-10-03 — — WO disclosed
US-20240294384-A1 MATERIAL, METHOD FOR PRODUCING MATERIAL AND FUNCTIONAL MATERIAL SEKISUI CHEMICAL CO., LTD. (JP) 2024-09-05 — — US disclosed
EP-4397156-A1 A METAL ORGANIC FRAMEWORK (MOF) GLASS COMPOSITE COMPRISING METAL HALIDE PEROVSKITE The University of Queensland (AU) 2024-07-10 — — EP disclosed
EP-1545532-A2 HETEROCYCLIC COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2005-06-29 — — EP disclosed
EP-1545596-A2 USE OF HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ALLERGY AND ASTHMA JANSSEN PHARMACEUTICA N.V. (BE) 2005-06-29 — — EP disclosed
US-20040058934-A1 Heterocyclic compounds JANSSEN PHARMACEUTIC, N.V. (BE) 2004-03-25 — — US disclosed
WO-2004021999-A2 USE OF HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ALLERGY AND ASTHMA JANSSEN PHARMACEUTICA, N.V. (BE) 2004-03-18 — — WO disclosed
WO-2004022060-A2 (1H-BENZOIMIDAZOL-2-YL)-(PIPERAZINYL)-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS JANSSEN PHARMACEUTICA, N.V. (BE) 2004-03-18 — — WO disclosed
US-4662905-A REACTION PRODUCT OF COPPER SALT AND AN IMIDAZOLE, PYRAZOLE, TRIAZOLE, OR TETRAZOLE Itaru Todoriki, Director of Agency of Industrial Science and Technology (JP) 1987-05-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058934-A1 Heterocyclic compounds HRH4, HRH2, HRH1 PIN1 3002/4885MEN1 2203/4885KMT2A 3378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.